GENO Genovis AB

Genovis AB Initiates Sales of GlyCLICKâ„¢

LUND, Sweden--(BUSINESS WIRE)--

GlyCLICK is the first of a series of products based on a technology platform in which Genovis’ unique enzyme GlycINATOR® is combined with SiteClick™ technology from Life Technologies. GlyCLICK is a new technology in an expanding market for applications in antibody development, preclinical imaging and antibody drug conjugates (ADCs). The market for biopharmaceuticals is large and many pharmaceutical companies are looking for new and improved technologies that link chemotherapy to antibodies.

“We have now expanded our portfolio with a completely new type of product that will enable us to develop an additional business area. The strength of the GlyCLICK platform is its predictability: the antibody is always labeled at exactly the same site and with the same number of markers, resulting in a precise and accurate end product. The technology is also compatible with previously developed antibodies,” says Fredrik Olsson, Chief Executive Officer.

More about GlyCLICK

GlyCLICK is a platform for labeling antibodies at the same site (site specific) each time, with high reproducibility and with a broad range of applications. GlyCLICK can be used to label antibodies with markers for microscopy, preclinical imaging or to activate the antibody for labeling in chemotherapy. Labeling antibodies with various markers is a technique used in several areas of pharmaceutical research and development. With the technology currently available in the market, the marker can attach randomly in different places on the antibody, and in many cases it could have a negative effect on the function of the antibody. In addition, the position of the marker may vary depending on the antibody that is labeled. Using the new GlyCLICK technology platform, the label always attaches at precisely the same site and it is possible to label with many different markers, which makes the technology both versatile and scalable.

For more information about GlyCLICK http://www.genovis.com/products/glyclick/

SiteClick™

Genovis has a license for SiteClick from Life Technologies Corporation.

The SiteClick brand belongs to Life Technologies Corporation.

EN
27/04/2017

Underlying

GENOGenovis AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genovis AB

Free Trial
GENO GENOVIS AB

Genovis AB: 1 director

A director at Genovis AB bought 38,340 shares at 26.690SEK and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

05/27/25 May 27, 2025 1 EN
 PRESS RELEASE
Free
GENO GENOVIS AB

Genovis AB Initiates Sales of GlyCLICKâ„¢

LUND, Sweden--(BUSINESS WIRE)-- GlyCLICK is the first of a series of products based on a technology platform in which Genovis’ unique enzyme GlycINATOR® is combined with SiteClick™ technology from Life Technologies. GlyCLICK is a new technology in an expanding market for applications in antibody development, preclinical imaging and antibody drug conjugates (ADCs). The market for biopharmaceuticals is large and many pharmaceutical companies are looking for new and improved technologies that link chemotherapy to antibodies. ...

April 27, 2017 1 EN
EUR 18.48
GENO GENOVIS AB

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...

12/16/16 December 16, 2016 2 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch